Mexico - Delayed Quote MXN

WisdomTree Issuer ICAV - Artificial Intelligence Ucits Fund (WTAIN.MX)

1,445.03

0.00

(0.00%)

At close: December 11 at 9:18:37 AM CST

Retail investors are 'optimistic,' but 'realistic' going into 2025

Retail investors are feeling bullish about the market (^DJI, ^IXIC, ^GSPC) in 2025, eToro's fourth quarter Retail Investor Beat shows. eToro investment analyst Bret Kenwell joins Josh Lipton and Seana Smith on Market Domination to discuss how retail investors are thinking about the market headed into the new year. Kenwell says retail investors are "optimistic" but "realistic" for the new year. "They're looking to gain more exposure to crypto in 2025. They're looking to gain more exposure to equities in 2025. But they're also looking to raise some cash here," he says, later adding: "I think they're being prudent, but also, you know, keeping one foot in at least is so they keep getting taking advantage of, you know, more gains to come in 2025 if that is the case." The analyst reports that the survey found retail investors to prefer the financials sector and big-cap tech, including Magnificent Seven names and other artificial intelligence (AI) plays. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.

Yahoo Finance Video 5 hours ago

XLF

XLK

AAPL
Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.

Barrons.com 6 hours ago

LLY

NVO
European Stocks Edge Higher as Novo Nordisk Jumps From 2023 Low

(Bloomberg) -- European equities edged higher, boosted by a rebound in Danish drugmaker Novo Nordisk A/S, while investors continue to monitor what the US rates outlook means for the region. Most Read from BloombergHo Chi Minh City Opens First Metro Line After Years of DelayThe Architects Who Built MiamiReviving a Little-Known Modernist Landmark in BuffaloNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisThe Stoxx

Bloomberg 10 hours ago

^GSPC

NVO

DIISY
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.

Zacks 12 hours ago

NVO

LLY
Lilly's Zepbound Receives FDA Approval for Sleep Apnea

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

Zacks 13 hours ago

LLY

NVO

AMGN
Hot Obesity Drug Market Will Keep Investors Gripped Next Year

(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.Most Read from BloombergHo Chi Minh City Opens First Metro Line After Years of DelayThe Architects Who Built MiamiReviving a Little-Known Modernist Landmark in BuffaloNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNovo sh

Bloomberg 14 hours ago

LLY

ZEAL.CO

VKTX
Asian, European Markets Gain as Novo Nordisk Shines

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the weight-loss drug maker the previous week. The top performer in the index was Denmark’s Novo Nordisk, rising 8.9% after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema.

Barrons.com 15 hours ago

NVO
Trending tickers: Palantir, Spotify, Novo Nordisk, Honda and Direct Line

The latest investor updates on stocks that are trending on Monday

Yahoo Finance UK 16 hours ago

NOC

SPOT

PLTR
Top trending global stocks of 2024

Here are the stocks that have reflected the key market trends of 2024 and have been closely watched by investors.

Yahoo Finance UK 21 hours ago

TCS.NS

BABA

BABAF
Is Merck the Next Big Weight-Loss Stock?

Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just inked a license agreement with a Chinese biopharma company called Hansoh Pharma that could presage its merits as a weight-loss stock in the coming years. Per the terms of that deal, Merck will get the exclusive worldwide rights to develop and then sell HS-10535, a preclinical-stage candidate that could potentially be useful for treating a few high-profile cardiometabolic disorders, including obesity and perhaps type 2 diabetes.

Motley Fool yesterday

NVO
This Simple ETF Could Turn $1,000 a Month Into Over $213,000

Invesco's QQQ is still a long-term winner for growth-oriented investors.

Motley Fool yesterday

^GSPC

QQQ

NVDA
Novo obesity data positive for Eli Lilly and Amgen, says UBS

UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also

TipRanks 2 days ago

NONOF

NVO

AMGN
Jefferies sees Novo dropping ‘at least’ 10%-15% on obesity data

Jefferies analyst Peter Welford says the first headline from Novo Nordisk’s (NVO) Phase III CagriSema obesity data “disappoint” with 20.4% absolute weight loss and patient adherence likely suggesting tolerability concerns. The firm’s buy-side survey suggested most anticipated 25%-27% absolute weight loss with fastrointestinal tolerability to be broadly similar to Wegovy. Jefferies notes its $7.75B peak CagriSema sales are well below the $20B-plus consensus. It expects the Novo shares to be down

TipRanks 2 days ago

NONOF

NVO
Weight loss seen with Novo’s CagriSema weaker than expected, says BofA

BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated compared to Eli Lilly’s (LLY) Zepbound as was expected. Weight loss in the REDEFINE 1 trial at about 20.4% is “essentially in line” with Zepbound at 21%, and not high enough to create a barrier relative to future competition, says the analyst. With that said, the data is still superior to Wegovy and sufficient

TipRanks 2 days ago

LLY

NONOF

NVO
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Santa Claus will soon be on his way delivering presents to kids around the world. Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Motley Fool 2 days ago

VRTX

NVO

ABBV
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.

Motley Fool 2 days ago

LLY

NVO
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.

For more than a year, Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema. On Friday, Novo released the results of a large Phase 3 trial of the drug. Patients lost only 22.7% of their body weight, on average, after about a year and a half.

Barrons.com 3 days ago

NVO

LLY
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Investor's Business Daily 3 days ago

LLY

VKTX

AMGN
Stock Market Today: Dow Jones, Other Indexes Rebound But Trim Gains; Nvidia Climbs After Bullish Report (Live Coverage)

The Dow Jones Industrial Average and other major stock indexes closed higher but off session highs Friday after a soft inflation report provided a bullish backdrop, while efforts continued to avert a partial government shutdown. The Dow industrials added nearly 500 points, or 1.2%. The S&P 500 climbed 1.1% and the Nasdaq composite gained 1% but had been up as much as 2%.

Investor's Business Daily 3 days ago

DJT

DJTWW

NONOF
Top Stock Movers Now: Carnival, US Steel, Occidental Petroleum, and More

Major U.S. indexes gained at midday Friday after the Federal Reserve’s favored measure of inflation came in below estimates.

Investopedia 3 days ago

CUK

OXY

X

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

WisdomTree Issuer ICAV - Artificial Intelligence Ucits Fund (WTAIN.MX)

Related ETF News

Retail investors are 'optimistic,' but 'realistic' going into 2025

Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.

European Stocks Edge Higher as Novo Nordisk Jumps From 2023 Low

NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Lilly's Zepbound Receives FDA Approval for Sleep Apnea

Hot Obesity Drug Market Will Keep Investors Gripped Next Year

Asian, European Markets Gain as Novo Nordisk Shines

Trending tickers: Palantir, Spotify, Novo Nordisk, Honda and Direct Line

Top trending global stocks of 2024

Is Merck the Next Big Weight-Loss Stock?

This Simple ETF Could Turn $1,000 a Month Into Over $213,000

Novo obesity data positive for Eli Lilly and Amgen, says UBS

Jefferies sees Novo dropping ‘at least’ 10%-15% on obesity data

Weight loss seen with Novo’s CagriSema weaker than expected, says BofA

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Stock Market Today: Dow Jones, Other Indexes Rebound But Trim Gains; Nvidia Climbs After Bullish Report (Live Coverage)

Top Stock Movers Now: Carnival, US Steel, Occidental Petroleum, and More